| Editor's Choice: Interventional Cardiology | The FDA has been busy this month. Review some of the biggest FDA-related stories of October, including big news from scPharmaceuticals, Abiomed, Bristol Myers Squibb and MedAlliance, in our monthly roundup. The FDA has been busy this month. Review some of the biggest FDA-related stories of October, including big news from scPharmaceuticals, Abiomed, Bristol Myers Squibb and MedAlliance, in our monthly roundup. | | |
| The study's authors examined data from nearly 10,000 patients for a new meta-analysis, presenting their findings in JTCVS Open. The study's authors examined data from nearly 10,000 patients for a new meta-analysis, presenting their findings in JTCVS Open. | | |
| Bhatt succeeds Valentin Fuster, MD, PhD, who has held the position since 2006 and will now serve in a more advisory role at Mount Sinai Heart. Bhatt succeeds Valentin Fuster, MD, PhD, who has held the position since 2006 and will now serve in a more advisory role at Mount Sinai Heart. | | |
| The acquisition includes an initial investment of $35 million and an upfront closing payment of $200 million. By 2029, if the companies reach all targeted regulatory and commercial milestones, the acquisition could cost Cordis up to $1.135 billion in all. The acquisition includes an initial investment of $35 million and an upfront closing payment of $200 million. By 2029, if the companies reach all targeted regulatory and commercial milestones, the acquisition could cost Cordis up to $1.135 billion in all. | | |
| Researchers examined data from patients who underwent high-risk PCI with either an Impella heart pump or an intra-aortic balloon pump. Researchers examined data from patients who underwent high-risk PCI with either an Impella heart pump or an intra-aortic balloon pump. | | |
| Two late-breaking clinical trials presented at the VIVA Foundation’s VIVA22 conference in Las Vegas highlighted the impact drug-coated balloons can make on patient outcomes. Two late-breaking clinical trials presented at the VIVA Foundation’s VIVA22 conference in Las Vegas highlighted the impact drug-coated balloons can make on patient outcomes. | | |
| Fitzgerald, a leading figure in interventional cardiology, praised the company's potential to improve patient outcomes and quality of life. Fitzgerald, a leading figure in interventional cardiology, praised the company's potential to improve patient outcomes and quality of life. | | |
| Researchers tracked outcomes data and imaging results from nearly 4,000 TEER patients, sharing their findings in the Journal of the American College of Cardiology. Researchers tracked outcomes data and imaging results from nearly 4,000 TEER patients, sharing their findings in the Journal of the American College of Cardiology. | | |
| |
|
| ![]() | |
|
